TOPRA - The Organisation for Professionals in Regulatory Affairs’ Post

New Repeat #Prescribing Toolkit launched by Royal Pharmaceutical Society & Royal College of General Practitioners to enhance safety & efficiency. With 1 billion+ prescriptions annually, the toolkit aims to cut waste & improve patient care. A major step towards tackling overprescribing! #pharmacy #NHS 🔗https://lnkd.in/expWBRyz

New Repeat #Prescribing Toolkit launched by Royal Pharmaceutical Society & Royal College of General Practitioners to enhance safety & efficiency. With 1 billion+ prescriptions annually, the toolkit aims to cut waste & improve patient care. A major step towards tackling overprescribing! #pharmacy #NHS #medsafety 🔗https://lnkd.in/expWBRyz

📢Swissmedic is efficient, competitive and fit for purpose according to SFAO 🔎The Swiss Federal Audit Office (SFAO) conducted audits of two core processes at Swissmedic between November 2022 and July 2023. In both cases, it received very good ratings. The Agency for Therapeutic Products is well positioned for both the authorisation and vigilance of medicinal products, has a very good international network, and has efficient, properly functioning processes that are under constant development. Further details are available in the reports published by the SFAO👇 📄Prüfung des Zulassungs- und Vergütungsprozesses von Arzneimitteln 🔗 https://bit.ly/3NY6FK2 📄Prüfung des Vigilance-Systems für Arzneimittel und Impfstoffe 🔗 https://bit.ly/3NY4ki5

📢 New EFPIA - European Federation of Pharmaceutical Industries and Associations Data Highlights Unequal Access to Medicines Across Europe EFPIA's latest reports, developed in collaboration with Charles River Associates (CRA), reveal significant disparities in the time it takes for European patients to access new medicines, with the average time being 531 days. This ranges from 126 days in Germany to 804 days in Poland. These delays are caused by multifactorial reasons, including slow regulatory processes, varying health technology assessments, and different reimbursement practices across countries. External reference pricing (ERP) further exacerbates these delays. #CRA #LifeSciences #EFPIA #Pharma

We all want trust in the medicines we take to improve ours and our families' health. This was huge motivator in the European Medicines Agency's (EMA) giant leap forward with Policy 70, setting a new standard for transparency in the medical field. Our blog breaks down everything you need to know about this groundbreaking policy. From enhancing public health to meeting the growing demand for trust in the pharmaceutical and regulatory landscape, we've got you covered. Read more ⬇️ #emapolicy70 #transparency #healthcareinnovation

In February, a spike in online HCP respiratory conversations highlighted concerns over asthma misinformation. Several HCPs, including Ravvijjot Saggu, pharmacist and Chair of UK Clinical Pharmacy Association (UKCPA), highlighted the problem. He stressed the severity of the disease and corrected what was wrong. Our respiratory tracker outlines more HCP's concerns about medical misinformation that pharmaceutical companies could help tackle. (Link in comments) Better listening for better health. #pharma #healthcare #medicine

FIP highlights importance of supporting a service-oriented pharmacy practice model

Tune into tomorrow’s webinar, 2 pm to 2.30 pm AEDT, on the Department of Industry, Science and Resources new Medicines Repurposing Program which will identify new uses for existing medicines registered on the Australian Register of Therapeutic Goods, working with clinicians, health organisations, patient groups, researchers, pharmaceutical companies and other interested members of the public to identify opportunities for repurposing.

UK MHRA International Recognition Procedure - IRP (Rapid Approval Regulatory Pathway) 🚄 Medicines and Healthcare products Regulatory Agency (MHRA) grants first approval via the new International Recognition Procedure in 30 days 🗓️ The product was initially reviewed by the European Medicines Agency (EMA) and received a positive opinion from the EMA’s Committee for Medicinal Products for Human Use (CHMP) on 25 January 2024. The MHRA considered the assessment made by the European regulator as part of its own review, facilitating a rapid approval process in 30 days. Reference Regulators (RR) under IRP Therapeutic Goods Administration, Health Canada | Santé Canada, Swissmedic, Health Sciences Authority, PMDA, FDA and European Medicines Agency Timelines 🕛 The RR approval must have been granted within the previous 2 years then 60 days approval process. The RR approval must have been granted within the previous 10 years then 110 days approval process. More information about the first approval via IRP 🔗 https://lnkd.in/gByakpgs For more information about IRP please check my previous post regarding IRP 🔗 https://lnkd.in/gDm87Rzb #regulatorypathway #regulatorystrategy #regulatoryharmonization #regulatorycollaboration #patientcentricity #irp #ukmhra #ema #usfda #tga #healthcanada #pmda #hsa #swissmedic

Totally recommend tuning in. write your specific questions during the registration. They actually answer them during the seminar. Benjamin Dwyer this it.